Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
LI

NASDAQ · LIVN

LivaNova PLC

Healthcare · Medical - Devices

$78.97

Down-$2.28 (-2.81%)

Updated Oct 31, 2026, 3:07 PM

SID Score

6.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.49B
P/E ratio
-16.05
Dividend yield
0.00%
52-week range
$48.82 – $85.76
Volume
575.6K
Avg. volume
568.98K

Price performance · LIVN

LIVN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

LIVN closed at $78.97 after 21 trading sessions, up 5.20% for the selected period.

Last close
$78.97
Period change
+5.20%
Period low
$74.93
Period high
$81.27
Daily close
View OHLC price history
LIVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$81.38$82.87$78.41$78.97575.6K
Oct 29, 2026$81.92$82.28$81.05$81.25483.32K
Oct 28, 2026$79.88$81.92$79.88$80.66550.58K
Oct 27, 2026$81.04$81.12$80.05$80.38383.6K
Oct 26, 2026$80.90$81.63$79.67$80.62362.38K
Oct 23, 2026$80.72$81.77$80.3275$80.90572.06K
Oct 22, 2026$78.70$81.42$78.35$81.27522.98K
Oct 21, 2026$79.83$81.245$78.005$78.44556.32K
Oct 20, 2026$78.86$80.685$78.85$79.71583.8K
Oct 19, 2026$78.02$78.835$77.39$78.14387.1K
Oct 16, 2026$78.69$79.3093$77.18$77.58774K
Oct 15, 2026$76.90$79.11$76.195$78.50737.98K
Oct 14, 2026$75.82$77.28$75.13$76.08464.61K
Oct 13, 2026$77.34$78.10$76.12$76.37563.22K
Oct 12, 2026$76.12$77.35$75.99$77.271.03M
Oct 9, 2026$76.12$77.66$75.625$76.39339.43K
Oct 8, 2026$75.45$76.25$74.23$75.91467.18K
Oct 7, 2026$75.06$76.26$74.44$75.93692.1K
Oct 6, 2026$76.80$76.80$74.58$74.93424.53K
Oct 5, 2026$75.555$76.90$74.23$76.43558.95K
Oct 2, 2026$75.68$76.765$74.635$75.07528.52K

Latest LIVN news

The latest Smart Investors Daily articles mentioning LIVN.

Stock researchCompany · Overview

LIVN research

Overview

Company profile and research snapshot.

Company profile

UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$55.00
Implied upside
—
Analysts
—
LIVN recent ratings
DateFirmRatingTarget
Oct 7, 2026BarclaysOverweight—
Sep 2, 2026Piper SandlerOverweight—
Aug 5, 2026NeedhamBuy—
Jul 15, 2026MizuhoOutperform—
Jul 1, 2026Freedom Capital MarketsHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 23, 2026

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

GLOUCESTER, England, October 23, 2026--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, "CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,"1 re

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By